Mindset Planning Trials for its Advanced Pre-Clinical Psychedelic MSP-1014! by The Investors Coliseum published on 2022-05-14T10:52:15Z On Today’s Sunday Soundbite we hear from Joseph Araujo (Chief Scientific Officer) talk to investors today about the exciting news that Mindset is now moving forward with plans for Clinical Trials of its Advanced Pre-Clinical Psychedelic, MSP-1014. Find out what this means for the company as they advance to this monumental next stage! About Mindset Pharma Inc: (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) Founded by domain experts in drug development, medicinal chemistry and capital markets, Mindset Pharma is a Toronto-based research and development company that utilizes a proprietary platform for discovering and developing novel and patentable next-generation psychedelic drug candidates for the treatment of neurological and psychiatric disorders. For a Full Profile View & Press Release of Mindset Pharma Inc. Visit: https://theinvestorscoliseum.com/featured-companies/mindset-pharma-inc/ Genre Business Comment by The Investors Coliseum Great Update 2022-05-14T10:53:33Z